Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Burrill & Company Appoints New Head of Its Merchant Banking Group and Augments Its GroupJune 06, 2011
SAN FRANCISCO, CA--(Jun 6, 2011) - Burrill & Company is pleased to announce that Mr. Stephen A. Hurly has joined the company as Managing Director and CEO of Burrill Merchant Banking. Mr. Hurly was previously with the Philadelphia-based investment banking firm Boenning & Scattergood Inc., joining them in 2008 as a Managing Director and Global Head of the firm's Health Care Investment Banking Practice. Prior to that appointment, Mr. Hurly was the Managing Director and Head of the Life Sciences Group at Janney Montgomery Scott. His earlier investment banking experience was with Hambrecht & Quist in San Francisco, where he closed over 30 public and private financings as well as M&A transactions, eventually becoming a member of the executive offices.
Mr. Hurly is an expert in strategic transactions and associated capital raising, and has completed over 100 deals with an aggregate value over $10 billion and over $400 million in capital. He has an M.B.A. from the University of Chicago and a B.S. in Engineering from Swarthmore College.
Also joining Burrill Merchant Banking from Boenning & Scattergood are Mr. David Parke and Dr. Wenyong Wang. Mr. Parke is joining Burrill Merchant Banking as Managing Director to assist private and public company clients in structuring and closing private placement financing transactions. Previously, David was Managing Director at Boenning & Scattergood where he focused on financings for life sciences companies, including public offerings and private placements. Prior to that he was with Mufson Howe Hunter & Company, where he was instrumental in launching and developing the firm's emerging growth practice. He also served with the corporate finance department of Investec, Inc. and its predecessor, Pennsylvania Merchant Group. Mr. Parke has managed or participated in 40 public offerings and private placements, raising more than $1 billion for emerging growth clients. In addition, he has managed mergers and acquisitions assignments ranging from $5 million to $500 million. Mr. Parke received his M.B.A. with Honors from The Wharton School of the University of Pennsylvania, and graduated summa cum laude and Phi Beta Kappa from Lehigh University with a B.S. in Finance.
Dr. Wang, who has been involved in the scientific and financial evaluation of public and private biotechnology, pharmaceutical and medical device companies, joins the Merchant Banking team as a Director. His previous investment banking experience was gained with Janney Montgomery Scott in Philadelphia where he worked as a Vice President. He also has significant industry experience being involved in drug Research and Development at GlaxoSmithKline for over six years. Dr. Wang has a Ph.D. in Organic Chemistry from the University of Pennsylvania, a B.S. from Shandong University, and an M.B.A from Penn State University.
"We are delighted to have attracted Stephen, who is recognized as an expert in strategic transactions and associated capital raising, to lead our Merchant Banking practice," said G. Steven Burrill, CEO of Burrill & Company. "His extensive industry relationships and global transaction experience is a perfect fit with our ongoing and growing globally-focused life sciences activities. He joins a rapidly growing Burrill Merchant Banking Team, now strengthened by the addition of Mr. Parke and Dr. Wang, and he will make an important contribution by leading our banking practice in growing our range of product offerings for life sciences companies," concluded Mr. Burrill.
About Burrill Merchant Banking
Burrill Merchant Banking provides life sciences companies with access to financial resources through proprietary sources of global capital and a blend of complementary financial advisory services such as: Committed Equity Lines of Credit, PIPEs, traditional equity offerings and select direct investments by Burrill Ventures or Burrill Private Equity. In 2010, the company's service and product offerings were broadened to enhance company access to public capital markets through the establishment of an Institutional Division. Our team has extensive experience and a comprehensive network to help life science companies identify and access companies strategic to building their businesses.
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia.
Upcoming Burrill & Company Events
The 2nd Annual Burrill Pan-Asia Life Sciences Meeting
June 26, 2011. Washington, D.C.
The Burrill Personalized Medicine Meeting
October 3-4, 2011. Burlingame, CA